Get the Stockscreener App
9.59
0.63%
0.06
Amneal Pharmaceuticals Inc stock is traded at $9.59, with a volume of 1.72M.
It is up +0.63% in the last 24 hours and up +20.48% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$9.53
Open:
$9.65
24h Volume:
1.72M
Relative Volume:
1.08
Market Cap:
$3.01B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-14.09
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+1.48%
1M Performance:
+20.48%
6M Performance:
+22.48%
1Y Performance:
+19.13%
1-Day Range:
$9.565
$9.79
1-Week Range:
$9.22
$9.79
52-Week Range:
$6.685
$9.79
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
9.59 | 2.91B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Amneal Pharmaceuticals Inc. Breaks Losing Streak — Is the Trend ReversingGap Up & Comprehensive Market Scan Insights - newsyoung.net
Amneal Pharmaceuticals Inc. Reversal Rally May Surprise BearsMarket Movers & Safe Capital Growth Tips - sundaytimes.kr
How Amneal Pharmaceuticals Inc. stock performs during market volatility2025 Top Gainers & Intraday High Probability Setup Alerts - thegnnews.com
Is Amneal Pharmaceuticals Inc. showing insider buyingNew Guidance & Breakout Confirmation Alerts - thegnnews.com
Major Insider Sales Shake Up Amneal Pharmaceuticals! - TipRanks
Amneal Pharma EVP Shah sells $666k in shares By Investing.com - Investing.com Canada
Quant Funds Rotate Into Amneal Pharmaceuticals Inc. StockJuly 2025 Final Week & Weekly Stock Performance Updates - sundaytimes.kr
Can Amneal Pharmaceuticals Inc. expand into new marketsWeekly Investment Report & Weekly Stock Breakout Alerts - kangso.co.kr
Amneal Pharmaceuticals stock hits 52-week high at 9.48 USD By Investing.com - Investing.com Australia
Amneal Pharmaceuticals stock hits 52-week high at 9.48 USD - Investing.com
Wall Street Analysts See a 27.66% Upside in Amneal (AMRX): Can the Stock Really Move This High? - Yahoo Finance
Avantor, Viatris, and Amneal Stocks Trade Up, What You Need To Know - Yahoo Finance
Amneal Will End Sale of Calcium-Drip Copies in Patent-Suit Pact - Bloomberg Law News
Amneal Pharmaceuticals Insider Sold Shares Worth $302,596, According to a Recent SEC Filing - MarketScreener
Here's Why Momentum in Amneal (AMRX) Should Keep going - Yahoo Finance
AMRX Q2 Deep Dive: New Product Launches and Specialty Momentum Shape Guidance - ca.finance.yahoo.com
Revvity, Avantor, Azenta, Bio-Techne, and Amneal Shares Skyrocket, What You Need To Know - TradingView
Is Amneal Pharmaceuticals Inc. forming a bullish divergenceGuaranteed Profit Setup Watchlist - newsyoung.net
Truist Financial Maintains a Buy on Amneal Pharmaceuticals (AMRX) With an $8 PT - MSN
Brown Rudnick Represents Amneal Pharmaceuticals LLC in a $2.1 Billion Term Loan Credit Facility - Brown Rudnick
‘Made-In-America’ Amneal Does Not Fear Trump’s Proposed ‘Chaotic’ Triple-Digit Tariffs On Drugs - insights.citeline.com
Amneal Pharmaceuticals Inc. Stock Poised for Technical ComebackRisk Controlled Picks With Real Returns Outlined - beatles.ru
Published on: 2025-08-11 02:04:05 - metal.it
Amneal raises 2025 guidance and targets $300M–$500M peak CREXONT sales as new launches accelerate - MSN
Published on: 2025-08-10 19:02:24 - metal.it
Earnings Beat: Amneal Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - ca.finance.yahoo.com
Amneal 2025 Q2 Earnings Strong Performance as Net Income Surges 112% - AInvest
Amneal (AMRX) Q2 EPS Jumps 56% - AOL.com
Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Amneal Pharma Reports Strong Q2 2025 Results - The Globe and Mail
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Amneal Pharmaceuticals Reports Strong Q2 2025 Results - The Globe and Mail
Amneal Pharmaceuticals Q2 2025 Earnings: EPS Beats Estimates, Revenue Falls Short - AInvest
Amneal: Q2 Earnings Snapshot - New Haven Register
Amneal Pharmaceuticals Inc (AMRX) Q2 2025 Earnings Call Highlights: Strong Growth and Raised ... By GuruFocus - Investing.com Canada
Amneal Pharma’s Optimistic Q2 Earnings Call Highlights - TipRanks
Amneal Pharmaceuticals' 2025Q2 Earnings Call: Key Contradictions on RYTARY, CREXONT, and Margin Strategies - AInvest
AMNEAL PHARMACEUTICALS Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Amneal Pharma Q2 2025 EPS beats forecast - Investing.com
Earnings call transcript: Amneal Pharma Q2 2025 EPS beats forecast By Investing.com - Investing.com South Africa
Amneal Pharmaceuticals Stock Rises Amid Growth Signals - TipRanks
Amneal Pharmaceuticals shares rise 5.53% intraday after revising earnings guidance and raising fiscal 2025 outlook. - AInvest
Transcript : Amneal Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Amneal Raises Outlook Even As Revenue Falls Short - Finimize
Knight Therapeutics Submits CREXONT Marketing Authorization Application in Mexico - AInvest
Amneal Pharmaceuticals Lifts Annual Earnings Outlook As Q2 Net Income Surges; Pre-Market Stock Up - Nasdaq
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates - Yahoo Finance
Amneal Pharmaceuticals Surpasses Q2 Earnings ExpectationsNews and Statistics - IndexBox
Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2025 - MarketScreener
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amneal Pharmaceuticals Inc Stock (AMRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Konidaris Tasos | Executive Vice President & CFO |
Aug 15 '25 |
Sale |
9.43 |
219,159 |
2,066,669 |
122,152 |
| Konidaris Tasos | Executive Vice President & CFO |
Aug 13 '25 |
Sale |
9.22 |
161,365 |
1,487,785 |
460,517 |
| Konidaris Tasos | Executive Vice President & CFO |
Aug 14 '25 |
Sale |
9.30 |
119,206 |
1,108,616 |
341,311 |
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):